Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Voya Financial Advisors Inc.

Voya Financial Advisors Inc. trimmed its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 9.1% during the third quarter, Holdings Channel.com reports. The fund owned 1,768 shares of the company’s stock after selling 177 shares during the period. Voya Financial Advisors Inc.’s holdings in Medpace were worth $586,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Signaturefd LLC grew its position in shares of Medpace by 4.9% in the 2nd quarter. Signaturefd LLC now owns 559 shares of the company’s stock worth $230,000 after acquiring an additional 26 shares in the last quarter. Wealth Alliance boosted its position in shares of Medpace by 2.9% in the second quarter. Wealth Alliance now owns 970 shares of the company’s stock valued at $399,000 after acquiring an additional 27 shares during the period. Centaurus Financial Inc. lifted its stake in Medpace by 2.0% during the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock worth $505,000 after purchasing an additional 29 shares during the period. Commonwealth Equity Services LLC increased its position in shares of Medpace by 0.7% during the 2nd quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock worth $1,787,000 after purchasing an additional 32 shares in the last quarter. Finally, Lindenwold Advisors INC raised its position in Medpace by 1.6% in the 3rd quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock valued at $676,000 after purchasing an additional 32 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Trading Up 2.4 %

NASDAQ:MEDP opened at $350.53 on Friday. The firm has a fifty day simple moving average of $338.31 and a two-hundred day simple moving average of $369.55. The stock has a market capitalization of $10.89 billion, a price-to-earnings ratio of 30.69, a PEG ratio of 1.92 and a beta of 1.37. Medpace Holdings, Inc. has a 12 month low of $277.72 and a 12 month high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. During the same quarter in the previous year, the company posted $2.22 earnings per share. The company’s quarterly revenue was up 8.3% on a year-over-year basis. Equities analysts predict that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Truist Financial lowered their price objective on Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research report on Monday, October 14th. William Blair reiterated an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Redburn Atlantic started coverage on Medpace in a report on Monday, October 14th. They issued a “buy” rating and a $404.00 price objective for the company. UBS Group lowered Medpace from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $420.00 to $350.00 in a research note on Friday, September 27th. Finally, Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and lowered their price target for the company from $415.00 to $345.00 in a report on Wednesday, September 25th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $380.56.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.